Azenta, Inc. Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2023. The filing is an annual report, not a standalone fiscal fourth-quarter report; fourth-quarter information is provided selectively, including share repurchases. Azenta operates exclusively in life sciences following the February 2022 sale of its semiconductor automation business for approximately $2.9 billion. Its two reportable segments were Life Sciences Products and Life Sciences Services.
Business Context
- Provides automated cold storage, temperature-controlled transport, consumables, instruments, sample repository solutions, informatics, genomic sequencing, synthesis and related services.
- Approximately 3,500 workers, sales in approximately 150 countries and approximately 13,000 customers as of September 30, 2023.
- Fiscal 2023 acquisitions included B Medical Systems, acquired October 3, 2022 for $432.2 million including contingent consideration, and Ziath, acquired February 2, 2023 for $16.0 million. B Medical contributed $113.1 million of revenue and a $26.5 million net loss in fiscal 2023.
Key Financial Metrics
| Fiscal year ended September 30 | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $665.1 million | $555.5 million | +19.7% |
| Gross profit | $263.1 million | $255.6 million | +3.0% |
| Gross margin | 39.6% | 46.0% | Down 6.4 points |
| Operating loss | $(73.1) million | $(24.7) million | Loss increased |
| Loss from continuing operations | $(12.9) million | $(11.3) million | Loss increased |
| Net income (loss) | $(14.3) million | $2.13 billion | Prior year included semiconductor sale gain |
| Basic and diluted loss per share | $(0.22) | $28.48 | Prior year included discontinued operations |
| Operating cash flow | $17.5 million | $(466.0) million | Improved |
| Capital expenditures | $39.4 million | $73.4 million | Down |
- Segment revenue: Life Sciences Products revenue was $305.2 million, up 53.2%, primarily because of B Medical. Life Sciences Services revenue was $359.9 million, up 1.0%.
- Segment profitability: Products generated a $30.3 million operating loss versus $11.0 million of operating income in 2022. Services generated a $14.7 million operating loss versus $10.8 million of operating income.
- Margins: Products gross margin declined to 33.2% from 44.7%; Services gross margin declined to 45.0% from 46.7%. Drivers included B Medical purchase-accounting amortization, a $9.7 million inventory purchase-accounting charge, lower acquired-business margins, product mix, lower genomics sales and higher labor and investment costs.
- Non-operating items: Interest income increased to $43.7 million from $20.3 million due to higher interest rates and invested divestiture proceeds. There was no interest expense in 2023, compared with $4.6 million in 2022.
- Liquidity: At September 30, 2023, Azenta held $678.9 million of cash and cash equivalents, $450.2 million of marketable securities and $684.0 million of cash, cash equivalents and restricted cash. Approximately $569 million of cash, cash equivalents and restricted cash was held outside the United States.
- Debt: No outstanding debt was reported at September 30, 2023. The prior term loan was extinguished in 2022.
- Equity and repurchases: The company repurchased 17.5 million shares for $838.5 million during fiscal 2023. The remaining authorization was $662.0 million at September 30, 2023. An additional 2.1 million shares for $103.9 million were repurchased through the filing date, and management announced an intention to repurchase the remaining $500 million during fiscal 2024.
- Commitments: Non-cancelable commitments totaled $73.5 million, including $51.3 million of inventory purchase orders and $22.2 million of information-technology commitments.
Material Changes Versus the Prior Comparable Period
- Revenue growth was acquisition-driven: excluding acquisitions, Life Sciences Products revenue declined approximately 9%, while COVID-related revenue fell to approximately $7.7 million from $22 million.
- Operating performance deteriorated despite revenue growth because of lower gross margins, increased selling, general and administrative costs, higher research and development spending and continuing investments.
- Fiscal 2022 net income was unusually high because it included the approximately $2.56 billion gain on the semiconductor business divestiture. Fiscal 2023 included a $1.4 million loss from discontinued operations related primarily to adjustments and settlements of divestiture-related liabilities.
- Cash generation improved to positive operating cash flow, but total cash, cash equivalents and restricted cash declined by $357.3 million, primarily because of $844.1 million of financing outflows, principally share repurchases.
- Goodwill increased to $784.3 million from $513.6 million and net intangible assets increased to $294.3 million from $178.4 million, primarily due to acquisitions.
Guidance, Outlook, Risks and Unusual Items
- Management expects continued revenue growth from internally developed offerings, acquired businesses and potential future acquisitions, but the filing does not provide quantified fiscal 2024 revenue or earnings guidance.
- Effective October 1, 2023, the company reorganized into three business segments: Multiomics and Synthesis Solutions, Sample Management Solutions and B Medical Systems.
- The B Medical reporting unit’s carrying value approximated fair value as of October 1, 2023 and included approximately $107 million of goodwill, increasing sensitivity to underperformance, macroeconomic deterioration or adverse valuation assumptions.
- Management expects to begin phase two of its Suzhou, China facility in the second fiscal quarter of 2024, with estimated total costs of approximately $30 million over several years.
- Principal risks include macroeconomic weakness, customer spending reductions, foreign-exchange exposure, supply-chain disruptions, international trade restrictions, cybersecurity incidents, regulatory requirements, acquisition integration, customer concentration and impairment of goodwill or intangible assets.
- One customer accounted for more than 10% of fiscal 2023 revenue; the customer is a distributor serving end users in approximately 50 countries. The ten largest customers represented approximately 30% of revenue.
- The company accrued $2.5 million related to Edwards Vacuum claims, paid $0.8 million under a settlement of the 2023 claim and retained a $1.7 million accrual for the unresolved 2020 claim. Management does not expect a material adverse effect, but the outcome remains uncertain.
- PricewaterhouseCoopers issued unqualified opinions on the financial statements and internal control over financial reporting. B Medical, representing 17% of revenue and 5% of assets, was excluded from management’s internal-control assessment because it was acquired during fiscal 2023.
Most Important Facts to Verify
- Whether B Medical achieves sufficient growth and margin improvement to offset purchase-accounting amortization, integration costs and its fiscal 2023 loss.
- Whether Life Sciences Services, particularly genomics, returns to revenue and margin growth after its fiscal 2023 decline.
- The sustainability of positive operating cash flow after substantial share repurchases and planned additional repurchases.
- Liquidity accessibility, given the substantial foreign-currency and foreign-held cash balances and planned capital needs.
- Potential goodwill impairment, especially for B Medical, after the October 2023 segment reorganization.
- Progress and cost execution for the Suzhou facility expansion and other acquisition-related investments.
- Resolution of the Edwards Vacuum claim, tariff matters and other legal or regulatory contingencies.
- Future fiscal 2024 guidance and whether management provides quantified revenue, margin, cash-flow or capital-allocation targets.